SOFINNOVA VENTURE PARTNERS X, L.P. purchased 6.2% of their position (325K shares) of CINCOR PHARMA, INC. on the open market
Open‑market purchase worth $5.20M — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/13/2022ACC: 0001209191-22-003197
10% Owner
Since Jan 2022
-12.27M
Net shares
Net seller
$5.20M
Total acquired
1
Open market trades
1B · 0S
4
Total transactions
5.57M acquired · 17.85M disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+5.25M
Price / share
—
Trade value
—
% of position
New position
1/11/2022
0.00→5.25M
Common Stock
Indirect
Shares
+325K
Price / share
$16.00
Trade value
$5.20M
% of position
6.2%
1/11/2022
5.25M→5.57M
Total
Net shares
+5.57M
Net value
$5.20M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 1/11/2022 | C · Conversion | +5.25M | — | — | New position | 0.00 | 5.25M |
| Common Stock Indirect | 1/11/2022 | P · Purchase | +325K | $16.00 | $5.20M | 6.2% | 5.25M | 5.57M |
| Total | +5.57M | $5.20M | ||||||
Derivative Transactions2
Series A Preferred Stock
Indirect
Converts to
Common Stock
3.99M shares
Shares
−13.57M
Strike price
Held after
0.00
Exercisable
—
1/11/2022
Series B Preferred Stock
Indirect
Converts to
Common Stock
1.26M shares
Shares
−4.28M
Strike price
Held after
0.00
Exercisable
—
1/11/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A Preferred Stock Indirect | Common Stock3.99M shares | 1/11/2022 | C · Conversion | −13.57M | — | 0.00 | |
| Series B Preferred Stock Indirect | Common Stock1.26M shares | 1/11/2022 | C · Conversion | −4.28M | — | 0.00 |